Acrivon Therapeutics, Inc. (ACRV)
NASDAQ: ACRV · Real-Time Price · USD
2.240
-0.280 (-11.11%)
At close: Mar 28, 2025, 4:00 PM
2.400
+0.160 (7.14%)
After-hours: Mar 28, 2025, 7:59 PM EDT

Acrivon Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Net Income
-80.56-60.39-31.17-16.24-5.31
Depreciation & Amortization
1.010.540.360.040.01
Loss (Gain) From Sale of Investments
-3.78-3.32-0.7--
Stock-Based Compensation
14.2911.622.190.50
Other Operating Activities
0.930.780.731.42.17
Change in Accounts Payable
-3.593.61-0.250.80.08
Change in Other Net Operating Assets
6.024.53-1.29-0.470.24
Operating Cash Flow
-65.67-42.64-30.12-13.98-2.8
Capital Expenditures
-2.77-1.29-2.17-0.24-0.02
Investment in Securities
-4952.01-139.51--
Investing Cash Flow
-51.7750.72-141.68-0.24-0.02
Long-Term Debt Issued
----0.06
Net Debt Issued (Repaid)
----0.06
Issuance of Common Stock
70.090.78104.480-
Repurchase of Common Stock
-2.52-1.3---
Other Financing Activities
53.46-1.03-2.77--
Financing Cash Flow
121.03-1.55101.71112.222.89
Net Cash Flow
3.596.52-70.08980.07
Free Cash Flow
-68.44-43.93-32.28-14.22-2.82
Free Cash Flow Per Share
-2.02-1.99-7.83-8.16-1.97
Levered Free Cash Flow
-53.7-22.33-20.03-8.79-
Unlevered Free Cash Flow
-53.7-22.33-20.03-8.79-
Change in Net Working Capital
-3.82-8.75-0-1.03-
Updated Nov 13, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q